Abstract: The present disclosure relates to the field of radiotherapy, in particular, methods of and apparatus for treating cancer using ultra-high dose rate radiotherapy (FLASH). The apparatus may comprise a device configured to administer to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively. The device may be configured such that the treatment is sufficient to prevent further growth of the tumor for at least 10% longer than standard of care radiotherapy, induce at least 10% more tumor regression than standard of care radiotherapy and/or delay tumor regrowth by at least about 2 months longer than standard of care radiotherapy.
Type:
Grant
Filed:
October 18, 2022
Date of Patent:
July 29, 2025
Assignees:
Varian Medical Systems, Inc., Aarhus University, Central Denmark Region
Inventors:
Ricky Anupam Sharma, Sophia Pfister, Marta Vilalta, Brita Singers Sørensen, Per Rugaard Poulsen, Gael Luis Boivin
Abstract: Improved methods of assessing status of a solid-tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
March 13, 2018
Assignees:
Roche Molecular Systems, Inc., Aarhus University
Inventors:
Peter Meldgaard, Boe Sorensen, Julie Tsai, Wei Wen, Lin Wu
Abstract: The present invention provides a Nod-factor binding element, comprising one or more NFR polypeptides encoded by NFR genes, that are useful for providing non-nodulating plants with Nod-factor binding properties and triggering the endosymbiotic signalling pathway leading to nodulation. Furthermore the invention is useful for breeding for improved nodulation in nodulating legumes.
Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).
Type:
Application
Filed:
December 30, 2008
Publication date:
July 16, 2009
Applicants:
K.U. Leuven Research and Development, Aarhus Universitet, Aarhus University Hospital
Inventors:
Greta Van Den Berghe, Steffen Thiel, Troels Krarup Hansen
Abstract: The present invention provides a Nod-factor binding element, comprising one or more NFR polypeptides encoded by NFR genes, that are useful for providing non-nodulating plants with Nod-factor binding properties and triggering the endosymbiotic signalling pathway leading to nodulation. Furthermore the invention is useful for breeding for improved nodulation in nodulating legumes.
Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).
Type:
Application
Filed:
September 23, 2003
Publication date:
June 8, 2006
Applicants:
K.U. Leuven Research and Development, Aarhus University Hospital
Inventors:
Greta Van Der Berghe, Steffen Thiel, Troels Hansen
Abstract: The present invention relates to a retroviral vector which expresses a gene, e.g. for therapeutic use and/or of viral origin, under the translational control of an internal ribosomal entry site (IRES) resulting in the efficient translation of said gene.
Type:
Grant
Filed:
October 26, 2001
Date of Patent:
June 6, 2006
Assignee:
Aarhus University
Inventors:
Finn Skou Pedersen, Thomas Jesperson, Mogens Duch